Journal
CURRENT PHARMACEUTICAL DESIGN
Volume 19, Issue 18, Pages 3234-3247Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612811319180008
Keywords
Deubiquitinating enzymes; drug discovery; ubiquitin; infectious diseases; post-translational modifications
Categories
Funding
- MTA [013743-001]
- MAFES Special Research Initiatives (Edelmann) Control of Food-Borne Pathogens [160000-018100-027100-401120]
- National Science Foundation [Mississippi EPSCoR-0903787]
- Mississippi INBRE
- National Center for Research Resources [5P20RR016476-11]
- National Institute of General Medical Sciences from the National Institutes of Health [8 P20 GM103476-11]
Ask authors/readers for more resources
Deubiquitinating enzymes (DUBs) remove ubiquitin and ubiquitin-like modifications from proteins and they have been known to contribute to processes relevant in microbial infection, such as immune responses pathways. Numerous viral and bacterial DUBs have been identified, and activities of several host DUBs are known to be modulated during the infection process, either by a pathogen or by a host. Recently there have been attempts to take advantage of this feature and design therapeutic inhibitors of DUBs that can be used to limit the spread of infection. This review is focused on exploring the potential of DUBs in the treatment of infectious diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
